Abstract
Pegylated-interferon plus ribavirin is the standard treatment for chronic hepatitis C. Sustained virological response (SVR) rates of up to 80% are reported in genotype 2 and 3 chronic hepatitis C cases. Obesity, a modifiable risk factor, may have a deleterious effect on antiviral treatment. We performed this study to examine the efficacy and safety of pegylated-interferon and ribavirin therapy in Korean patients with genotype 2 and 3 chronic hepatitis C and to investigate the risk factors for nonresponse to antiviral treatment. A total of 121 patients were treated with peginterferon alpha-2a 180 mcg/week plus ribavirin 800 mg/day for 24 weeks. The end-of-treatment virologic response (ETVR), the SVR, the end-of-treatment biochemical response (ETBR), the sustained biochemical response (SBR), and the adverse events were analyzed. The ETVR and SVR were 94.1% and 89.1%, respectively. The ETBR was 80.2% and the SBR was 96%. Multivariate analysis showed that a body mass index of 25 and over was the only independent factor that affected the SVR (odds ratio=10.5, 95% confidence interval: 2.006-54.948, p=0.005). Twenty patients (16.5%) dropped out at the end of treatment, and 7 (5.8%) patients discontinued treatment because of treatment-...Continue Reading
References
Dec 1, 1992·Journal of Korean Medical Science·Y S KimY O Ahn
Jan 1, 1996·Obesity Research·R I WellensR M Siervogel
Mar 30, 1999·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·L F HouriganE E Powell
Mar 9, 2000·Journal of Pharmaceutical Sciences·C J Porter, S A Charman
Mar 25, 2000·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·A M Di Bisceglie
Dec 7, 2000·The New England Journal of Medicine·S ZeuzemM J Brunda
Apr 3, 2001·Journal of Hepatology·A D CloustonE E Powell
Jun 8, 2001·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·L E AdinolfiG Ruggiero
Jul 7, 2001·The New England Journal of Medicine·G M Lauer, B D Walker
Oct 5, 2001·Lancet·M P MannsJ K Albrecht
May 2, 2002·Journal of Gastroenterology and Hepatology·William Sievert
Sep 27, 2002·The New England Journal of Medicine·Michael W FriedJian Yu
May 23, 2003·Gastroenterology·Mark W Russo, Michael W Fried
Jun 26, 2003·The Journal of Infectious Diseases·Ming-Lung YuWen-Yu Chang
Aug 27, 2003·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Brian L BresslerJenny Heathcote
Apr 2, 2004·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Doris B StraderUNKNOWN American Association for the Study of Liver Diseases
May 27, 2006·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Michael R CharltonStephen A Harrison
Jul 21, 2007·The American Journal of Gastroenterology·Sharif MissihaUNKNOWN Canadian Pegasys Expanded Access Group
Sep 21, 2007·Gut·M PersicoA Iolascon
Mar 28, 2008·The Korean Journal of Hepatology·Heon Ju LeeHee Jung Moon
May 19, 2009·Gastroenterology·James E EverhartUNKNOWN HALT-C Trial Group
Aug 18, 2009·Nature·Dongliang GeDavid B Goldstein
Sep 15, 2009·Nature Genetics·Yasuhito TanakaMasashi Mizokami
Feb 3, 2011·Hepatology International·Venessa PattulloDavid K H Wong